MCS110
Total Payments
$1.3M
Transactions
43
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $103,523 | 5 | 0 |
| 2019 | $165,962 | 13 | 1 |
| 2018 | $404,032 | 13 | 2 |
| 2017 | $603,654 | 12 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 42 | 100.0% |
| Food and Beverage | $43.50 | 1 | 0.0% |
Payments by Type
Research
$1.3M
42 transactions
General
$43.50
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF MCS110 FOR TREATMENT OF PIGMENTED VILLONODULAR SYNOVITIS PVNS | Novartis Pharmaceuticals Corporation | $827,386 | 0 |
| A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $351,387 | 0 |
| A RANDOMIZED PHASE II STUDY OF MCS110 COMBINED WITH CARBOPLATIN AND GEMCITABINE IN ADVANCED TNBC | Novartis Pharmaceuticals Corporation | $98,068 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $286.50 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 3
- Transactions 43
About MCS110
MCS110 is a drug associated with $1.3M in payments to 3 healthcare providers, recorded across 43 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $103,523 was paid across 5 transactions to 0 doctors.
The most common payment nature for MCS110 is "Unspecified" ($1.3M, 100.0% of total).
MCS110 is associated with 4 research studies, including "A PHASE II RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF MCS110 FOR TREATMENT OF PIGMENTED VILLONODULAR SYNOVITIS PVNS" ($827,386).